Non-Coding RNAs and Extracellular Vesicles in Cancer Crosstalk: Diagnostic and Therapeutic Implications 2nd Edition

Dear Colleagues,

Extracellular vesicles (EVs) have been recognized as mediators of intercellular communication that allow horizontal information to be exchanged between cells. Non-coding RNAs (ncRNAs) are selectively packaged into EVs and transferred to proximal and distal target cells, inducing deep phenotypic changes. EVs play a pleiotropic role in cancer and ncRNAs contained in EVs are closely related to varied biological aspects of tumorigenesis. Recently, several findings indicate their key roles in cancer initiation and progression. The eclectic information acquired by evaluating the epigenetic biomarkers contained in EVs is an emerging field in oncology that may help with cancer screening, diagnosis, the identification of tumor subtypes, and the prediction of response to therapy and outcomes.

We invite you contribute a paper to our Special Issue “Non-Coding RNAs and Extracellular Vesicles in Cancer Crosstalk: Diagnostic and Therapeutic Implications”.

This Special Issue will discuss recent findings related to knowledge of biology, epigenetic regulation, early detection, innovations in personalized treatment and therapeutics targeting of ncRNAs, and the involvement of EV-ncRNAs in molecular mechanisms that contribute to cancer development.

Original research articles and reviews are welcome. Research areas may include, but are not limited to, submissions that cover topics relevant to ncRNAs shuttled by EVs, such as mechanism of action, EV engineering with ncRNAs, their functional roles in cancer cells, and clinical studies on the roles of EV-ncRNAs as potential biomarkers in cancer. Studies focusing on their emerging functional roles as targets for cancer treatments are especially welcome.

We look forward to receiving your contributions.

Dr. Simona Taverna
Dr. Giuseppe Cammarata
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.